According to CoinMeta, Hengrui Medicine announced that its subsidiary, Beijing Shengdi Medicine, has received notification from the National Medical Products Administration approving the market launch of Ruifexibai monoclonal antibody injection, a new drug of Class 1 independently developed by the company. This medication is used to treat homozygous familial hypercholesterolemia in adults and adolescents aged 12 and above, with the aim of reducing low-density lipoprotein cholesterol levels. To date, the cumulative investment in research and development for this drug project has amounted to approximately 303 million yuan.